Luis Filipe Da Silva Godinho

Title: Innovations of Luis Filipe Da Silva Godinho

Introduction

Luis Filipe Da Silva Godinho is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of immunotherapy, particularly in the development of specific binding molecules for HIV treatment. His work is characterized by innovative approaches that enhance the stability and efficacy of therapeutic agents.

Latest Patents

Luis Filipe Da Silva Godinho holds a patent for HIV specific binding molecules. This patent includes specific binding molecules, such as T cell receptors (TCRs), which bind the HLA-A*02 restricted peptide SLYNTVATL derived from the HIV Gag gene product, p17. The TCRs in this invention feature non-natural mutations within the alpha and/or beta variable domains compared to native TCRs. These specific binding molecules demonstrate improved stability and yield while retaining advantageous properties from their original forms. They are particularly valuable in developing soluble immunotherapeutic reagents for treating individuals infected with HIV.

Career Highlights

Luis Filipe Da Silva Godinho is associated with Immunocore Limited, a company focused on innovative immunotherapy solutions. His work at Immunocore has positioned him as a key player in the advancement of treatments for viral infections, particularly HIV.

Collaborations

Luis has collaborated with notable colleagues, including Marcin Dembek and Praveen Singh. Their combined expertise contributes to the innovative research and development efforts at Immunocore Limited.

Conclusion

Luis Filipe Da Silva Godinho's contributions to the field of immunotherapy, particularly through his patent on HIV specific binding molecules, highlight his role as an influential inventor. His work continues to pave the way for advancements in the treatment of HIV, showcasing the importance of innovation in medical research.